Diphenylhydantoin (Epanutin) is probably the most widely used anticonvulsant and, as with other anticonvulsants, it has been suggested that its effect is due to either increasing the level of gamma aminobutyric acid (GABA) available, or possibly acting itself as a GABA-like substance (Meldrum, 1975) . Saad et al. (1972) showed that diphenylhydantoin (DPH) increased cerebral hemisphere GABA content in mice.
Diphenylhydantoin (Epanutin) is probably the most widely used anticonvulsant and, as with other anticonvulsants, it has been suggested that its effect is due to either increasing the level of gamma aminobutyric acid (GABA) available, or possibly acting itself as a GABA-like substance (Meldrum, 1975) . Saad et al. (1972) showed that diphenylhydantoin (DPH) increased cerebral hemisphere GABA content in mice.
The effect of chronic or toxic administration of DPH is less clearly defined. Neurotoxicity is manifested in man by cerebellar signs, and although these effects can occur with small concentrations of DPH (Kutt et al., 1964; Gordon, 1969; Logan and Freeman, 1969; Glaser, 1972) , they usually occur when the serum level exceeds 30 ,tg/ml, while in patients with neurotoxicity, seizure control may be lost (Levy and Fenichel, 1965) . Sawaya et al. (1975) , investigating the action of anticonvulsants related to GABA metabolism in whole brain homogenates, found that DPH apparently activated GABA-T but inhibited succinic semialdehyde dehydrogenase. Histochemical studies (Karkos, 1975) on rat cerebellum revealed no change in the histochemistry of cerebellar succinic after six months' administration of phenytoin, despite morphological changes in Purkinje and Golgi cells. No reports have appeared on the histochemical changes on GABA induced by chronic diphenylhydantoin administration. Numerous studies (Fahn and C6te, 1968) show that GABA attains its highest level in the Purkinje cell layer, and that phenytoin is selectively accumulated in the cerebellum (Noach et al., 1958) . The rat cerebellum, therefore, and the Purkinje layer in particular, was chosen as indicator of the effect of DPH on GABA, and at the same time investigation of succinate activity was made in the same structures.
Material and methods
In the present study we have investigated the GABA and succinic content of the cerebellum in chronic and acute experiments. In the chronic experiments DPH was administered over 26 days. Animals used as controls received injections without DPH, and were injected over the same period with 1 ml of the vehicle (alcohol 10%, glycol 40%, distilled water 50%). Test animals were injected daily intraperitoneally with 1 ml diphenylhydantoin dissolved in the vehicle to give final concentrations of 0.25 mg/ml, 2.5 mg/ml, and 10 mg/ml. Adult female Chester Beattie rats with average weight 200 g i I g were used for both test and control groups. Group 1 received 1.25 mg/kg body weight, group 2 12.5 mg/kg body weight, and group 3 50 mg/kg body weight. The intraperitoneal route was chosen to ensure absorption rather than oral administration as other investigators have done.
The acute experiments were performed with toxic doses of DPH again administered intraperitoneally. These were given in three doses: 15 mg/ml (75 mg/kg 565 E. Hitchcock and T. Gabra-Sanders body weight), 17.5 mg/ml (87.5 mg/kg body weight), and 20 mg/ml (100 mg/kg body weight). All these injections rapidly induced marked toxic changes with failure of the animals to eat, paucity of movement, and, in high doses, gross ataxia. Animals in the first group (75 mg/kg) were sacrificed after four days because they looked ill although without obvious ataxia. The second group (87.5 mg/kg) was sacrificed after three days because of illness, and although there was no obvious ataxia the animals had a gross paucity of movement and generalised weakness. The group receiving the highest dose (100 mg/kg) was sacrificed after two days because of ill health and obvious ataxia.
At the end of the period of administration, all animals were anaesthetised with urethane 20 % (6 ml/kg body weight), and the whole cerebellum and brain stem were removed in vivo. The cerebellum was immediately mounted on a cryostat stub and rapidly frozen using liquid C02. This method was chosen as the level of GABA has been shown to increase rapidly after death (Lovell et al., 1963 
Results
No obvious toxic disorder appeared from the administration of the low doses of DPH in the first group. In the second group with acute experiments, rats with high doses were soon very sick and often ataxic.
The effect of DPH was to reduce the GABA content in Purkinje cells by a statistically significant amount (p < 0.001) when given in doses of more than 12.5 mg/kg body weight (Tables 1 and 2 ). A positive correlation between dose and GABA loss appeared to exist up to the critical level of 75 mg/kg (rank correlation coefficient +0.83) when the relationship became less marked. No change was noted in succinate at any dosage level.
Discussion
The investigation has shown that DPH produces a decrease of GABA in Purkinje cells, and confirms the findings of Karkos (1975) that there is no effect on succinic dehydrogenase activity in Purkinje cells. As he pointed out, however, this does not exclude the effect of the drug at other stages of the Krebs cycle, and our findings suggest that this is at the level of the gamma aminobutyric acid portion of the cycle. If DPH acted as an accelerator of GABA metabolism, high levels of succinate could be expected, but this was not the case. It is also possible that the reduction of GABA could be due to reduced activity in the synthesising enzyme glutamate decarboxylase (GAD). glutamic acid production and increase of GABA by DPH inhibits synaptic transmission and prevents the spread of discharge in convulsions, thus accounting for the anticonvulsant effect of the diphenylhydantoin (Woodbury, 1969) . Toxic doses of DPH, therefore, might produce increase of GAD as well as decrease of GABA. On the other hand, hydantoins, which are structural analogues of GABA, could compete with it (Meldrum, 1975) in high doses and thus result in decreased levels of GABA. It has been suggested that anticonvulsants exert their effect by activation of Purkinje cells which inhibit the epileptic activity in the cerebral-cerebellar pathways (Halpern and Julien, 1972; Julien, 1974; Bantli et al., 1976) . Our findings confirm the important relationship between the Purkinje cell and DPH, and suggest that this is the site of action of DPH and of the loss of epileptic control in overdosage.
